Literature DB >> 17294246

Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery.

Kent D Stewart1, Kevin Steffy, Kevin Harris, John E Harlan, Vincent S Stoll, Jeffrey R Huth, Karl A Walter, Emily Gramling-Evans, Renaldo R Mendoza, Jean M Severin, Paul L Richardson, Leo W Barrett, Edmund D Matayoshi, Kerry M Swift, Stephen F Betz, Steve W Muchmore, Dale J Kempf, Akhter Molla.   

Abstract

Two new proteins of approximately 70 amino acids in length, corresponding to an unnaturally-linked N- and C-helix of the ectodomain of the gp41 protein from the human immunodeficiency virus (HIV) type 1, were designed and characterized. A designed tripeptide links the C-terminus of the C-helix with the N-terminus of the N-helix in a circular permutation so that the C-helix precedes the N-helix in sequence. In addition to the artificial peptide linkage, the C-helix is truncated at its N-terminus to expose a region of the N-helix known as the "Trp-Trp-Ile" binding pocket. Sedimentation, crystallographic, and nuclear magnetic resonance studies confirmed that the protein had the desired trimeric structure with an unoccupied binding site. Spectroscopic and centrifugation studies demonstrated that the engineered protein had ligand binding characteristics similar to previously reported constructs. Unlike previous constructs which expose additional, shallow, non-conserved, and undesired binding pockets, only the single deep and conserved Trp-Trp-Ile pocket is exposed in the proteins of this study. This engineered version of gp41 protein will be potentially useful in research programs aimed at discovery of new drugs for therapy of HIV-infection in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294246     DOI: 10.1007/s10822-007-9107-1

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  16 in total

1.  Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.

Authors:  D M Eckert; V N Malashkevich; L H Hong; P A Carr; P S Kim
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

2.  Driving affinity selection by centrifugal force.

Authors:  J E Harlan; D A Egan; U S Ladror; S Snyder; M I Tang; A Buko; T F Holzman
Journal:  Assay Drug Dev Technol       Date:  2003-08       Impact factor: 1.738

3.  Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion.

Authors:  Christopher Cianci; David R Langley; Douglas D Dischino; Yaxiong Sun; Kuo-Long Yu; Anne Stanley; Julia Roach; Zhufang Li; Richard Dalterio; Richard Colonno; Nicholas A Meanwell; Mark Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-06       Impact factor: 11.205

4.  High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.

Authors:  Bong-Suk Jin; Won-Kyu Lee; Kwangseog Ahn; Myung Kyu Lee; Yeon Gyu Yu
Journal:  J Biomol Screen       Date:  2005-02

5.  Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.

Authors:  Gary Frey; Sophia Rits-Volloch; X-Q Zhang; Robert T Schooley; Bing Chen; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

6.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

Authors:  M Lu; S C Blacklow; P S Kim
Journal:  Nat Struct Biol       Date:  1995-12

7.  A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis.

Authors:  D S King; C G Fields; G B Fields
Journal:  Int J Pept Protein Res       Date:  1990-09

8.  Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.

Authors:  Hongmei Mo; Alex K Konstantinidis; Kent D Stewart; Tatyana Dekhtyar; Teresa Ng; Kerry Swift; Edmund D Matayoshi; Warren Kati; William Kohlbrenner; Akhteruzzaman Molla
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

9.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 10.  High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.

Authors:  Shuwen Liu; Shibo Jiang
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  4 in total

1.  Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Authors:  Shidong Chu; Hardeep Kaur; Ariana Nemati; Joseph D Walsh; Vivian Partida; Shao-Qing Zhang; Miriam Gochin
Journal:  ACS Chem Biol       Date:  2015-02-17       Impact factor: 5.100

2.  Design and characterization of swapped-domain constructs of HIV-1 glycoprotein-41 as receptors for drug discovery.

Authors:  Joseph D Walsh; Shidong Chu; Shao-Qing Zhang; Miriam Gochin
Journal:  Protein Eng Des Sel       Date:  2015-04       Impact factor: 1.650

3.  Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Authors:  Charles Sabin; Davide Corti; Victor Buzon; Mike S Seaman; David Lutje Hulsik; Andreas Hinz; Fabrizia Vanzetta; Gloria Agatic; Chiara Silacci; Lara Mainetti; Gabriella Scarlatti; Federica Sallusto; Robin Weiss; Antonio Lanzavecchia; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

4.  Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Authors:  Davide Corti; Johannes P M Langedijk; Andreas Hinz; Michael S Seaman; Fabrizia Vanzetta; Blanca M Fernandez-Rodriguez; Chiara Silacci; Debora Pinna; David Jarrossay; Sunita Balla-Jhagjhoorsingh; Betty Willems; Maria J Zekveld; Hanna Dreja; Eithne O'Sullivan; Corinna Pade; Chloe Orkin; Simon A Jeffs; David C Montefiori; David Davis; Winfried Weissenhorn; Aine McKnight; Jonathan L Heeney; Federica Sallusto; Quentin J Sattentau; Robin A Weiss; Antonio Lanzavecchia
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.